CRDL Cardiol Therapeutics Inc.
$1.01-3.81%
Last close: · regular session · Last 60 sessions
After-hours $1.03 +1.95% ·
- Float
- 115.4M
- Last filing
- 6-K · Nov 3, 2026
Latest SEC filings for CRDL
| 6-K | Foreign issuer report | |
| 6-K | Foreign issuer report | |
| 6-K | Foreign issuer report | |
| 6-K | Foreign issuer report | |
| F-10/A | ||
| SUPPL | ||
| 6-K | Foreign issuer report | |
| 6-K | Foreign issuer report | |
| F-10 | ||
| F-X |
Dilution today: new offering filings and reverse splits
Float: 115.4M shares. Latest SEC filing: 6-K on Nov 3, 2026. CRDL closed at $1.01 (-3.81%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CRDL in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: CA
- Exchange: NASDAQ
- Employees: 18
- Website: https://www.cardiolrx.com
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Latest CRDL news
- Cardiol Therapeutics drops after launching a $75M ATM offering Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.